Details:
Under the agreemeent, Abbott will commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia, the Middle East and Africa, and mAbxience will develop, manufacture and supply the biosimilar molecules.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Abbott Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 20, 2023
Details:
ORY-1001 (iadademstat) is a small oral molecule, which acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers.
Lead Product(s): Iadademstat,Undisclosed
Therapeutic Area: Oncology Product Name: ORY-1001
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Eurostars
Deal Size: $0.4 million Upfront Cash: Undisclosed
Deal Type: Funding December 16, 2022
Details:
The agreement covers VIVEbiotech long-term supplying lentiviral vectors for Xyphos’ upcoming clinical trial of its lead convertibleCAR-T™ program. This involves VIVEbiotech manufacturing lentiviral vectors for both preclinical and clinical phases.
Lead Product(s): Lentiviral vectors,convertible CAR-T cells
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Xyphos Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 04, 2020